Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন*
Indications:
EMISTAT 8 MG is indicated for the prevention and treatment of nausea and vomiting caused by cytotoxic chemotherapy, radiotherapy, and post-operative conditions.
Pharmacology:
EMISTAT contains Ondansetron, a selective 5-HT3 receptor antagonist. It blocks serotonin receptors in both the central nervous system (chemoreceptor trigger zone) and the gastrointestinal tract, thereby preventing nausea and vomiting.
Dosage & Administration:
-
Adults: 8 mg tablet 30 minutes before chemotherapy or radiation. Can be repeated every 8–12 hours depending on the treatment.
-
Postoperative nausea/vomiting: 16 mg (as 8 mg before surgery and 8 mg after).
-
Children: Dose adjusted by body weight.
Swallow the tablet whole with water, with or without food.
Interaction:
Interacts with apomorphine (contraindicated), and may alter plasma levels when used with phenytoin, carbamazepine, or rifampicin. Avoid concurrent use with drugs that prolong QT interval.
Contraindications:
Hypersensitivity to Ondansetron or other 5-HT3 antagonists. Concurrent use with apomorphine is contraindicated due to risk of profound hypotension.
Side Effects:
Headache, constipation, dizziness, and fatigue are common. Rare but serious side effects include QT interval prolongation, arrhythmia, and hypersensitivity reactions.
Pregnancy & Lactation:
Use during pregnancy only if clearly needed. Caution is advised during breastfeeding as it's not known whether Ondansetron is excreted in breast milk.
Precautions & Warnings:
Caution in patients with cardiac disorders, electrolyte imbalances (hypokalemia/hypomagnesemia), or hepatic impairment. ECG monitoring recommended in high-risk patients.
Therapeutic Class:
Antiemetic – 5-HT3 receptor antagonist
Storage Conditions:
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
.jpg)
.jpg)
Change Language